 OSAKA, Japan CAMBRIDGE, Mass.--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both Phase 2 studies early. This allows for the timely interpretation of the benefit risk profile of TAK-994 and to determine next steps for the progra 